Phenyllactic Acid Inhibiting Helicobacter pylori
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Helicobacter pylori infection, such as triple therapy, face challenges due to high antibiotic resistance rates and adverse side effects, necessitating a safe and effective alternative.
Innovation Solution
The use of phenyllactic acid as a drug component to inhibit Helicobacter pylori infection, including antibiotic-resistant strains, by targeting bacterial growth, urease activity, and gastric mucosal inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard triple therapy (clarithromycin and amoxicillin with PPI) is used to treat H. pylori infection, then the eradication rate is improved, but antibiotic resistance develops and adverse reactions occur
Solution Approach 1:
The patent employs phenyllactic acid, a naturally occurring short-chain fatty acid produced by lactic acid bacteria, as a disposable, non-antibiotic alternative to traditional antibiotic therapies. This organic acid acts as a temporary, non-toxic agent that inhibits H. pylori without causing long-term resistance or severe side effects, effectively replacing persistent antibiotic treatments with a safer, naturally derived compound
Solution Approach 2:
The patent changes the therapeutic parameter from antibiotic-based killing mechanisms to organic acid-based inhibition mechanisms. Phenyllactic acid works by lowering gastric pH and directly inhibiting H. pylori growth through its acidic properties, representing a fundamental shift in treatment approach from antimicrobial agents to pH-modulating natural products, thereby avoiding antibiotic resistance while maintaining therapeutic efficacy
2Reliability
If antibiotics are widely used to treat H. pylori infection, then the eradication rate is improved, but serious adverse reactions occur
Solution Approach 1:
The patent introduces phenyllactic acid as an intermediary substance that mediates between the host and H. pylori. This natural organic acid, produced by beneficial lactic acid bacteria in the gut, serves as a bridge that inhibits pathogenic bacteria while simultaneously supporting beneficial microbiota, thereby eliminating H. pylori without the harsh side effects of conventional antibiotics
Solution Approach 2:
The patent leverages the body's own natural defense mechanisms by utilizing phenyllactic acid, which is naturally produced by lactic acid bacteria present in the human gastrointestinal tract. This approach activates the body's intrinsic protective systems rather than introducing external toxic substances, allowing the immune system to work synergistically with natural antimicrobial compounds to eliminate H. pylori safely
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Phenyllactic acid demonstrates significant inhibitory effects on H. pylori, including reducing gastric mucosal inflammation and improving gastric microecology, with a minimum inhibitory concentration of 2.5 mg/mL, and shows potential for reducing antibiotic resistance and side effects.
Implementation Method 1
the phenyllactic acid has a significant inhibitory property against the H. pylori; the minimum inhibitory concentration (MIC) range of the phenyllactic acid for the H. pylori is 2.5 mg/mL
Implementation Method 2
the phenyllactic acid inhibits the urease activity of the H. pylori
Data Source
AI summary
The present invention belongs to the technical field of microorganisms. Provided in the present invention is use of phenyllactic acid in preparation of a drug for inhibiting Helicobacter pylori infection. The phenyllactic acid inhibits antibiotic-resistant Helicobacter pylori infection, and particularly can inhibit growth of Helicobacter pylori insensitive to metronidazole.